pharmaphorum

JULY 1, 2021

The Institute for Clinical and Economic Review (ICER) was very damning of Biogen’s new Alzheimer’s disease therapy Aduhelm when it issued its first report on the drug last month, and a swift update to its deliberations won’t be much comfort to the company.

Labelling 59

Labelling FDA 59

pharmaphorum

JANUARY 11, 2023

Eisai and Biogen have moved swiftly ahead with regulatory filings for their new Alzheimer’s therapy lecanemab in the EU, after getting a green light for the anti-amyloid beta antibody in the US late last week. “The upcoming 10-year plan for dementia must prioritise boosting stagnant dementia diagnosis rates and preparing the NHS.”

FDA 52

FDA 52

pharmaphorum

JUNE 8, 2021

The FDA “has failed in its responsibility to protect patients and families from unproven treatments with known harms” in approving Biogen’s Alzheimer’s disease drug Aduhelm. It said the drug was the first to treat the underlying mechanism in Alzheimer’s rather than addressing symptoms.

FDA 98

FDA Labelling 98

PharmaShots

MARCH 20, 2023

Craig Thompson: At the Society for Neuroscience Conference (SfN), we presented novel data on the identification and pharmacological evaluation of C101248, a novel, potent and selective inhibitor of tandem pore halothane-inhibited potassium channel 1 (THIK-1), which acts as a modulator of neuroinflammation in neurodegenerative disease.

Compounding 40

Compounding 40

Berkeley Pharma Tech

MARCH 26, 2023

Neurodegenerative Diseases Neurodegenerative diseases like Parkinson's and Alzheimer's are among the most crippling conditions that can afflict the nervous system. But the study of the brain is not just a scientific endeavor; it also has profound implications for society as a whole.

52

52

Hospital Pharmacy Europe

DECEMBER 7, 2022

However, during ageing, different iron complexes accumulate in brain regions and changes in iron homoeostasis result in altered cellular iron distribution and accumulation in diseases such as Alzheimer’s and Parkinson’s disease.

Hospitals 40

Hospitals 40

pharmaphorum

JUNE 2, 2021

Royalty also claims 80% of royalties and 100% of milestone payments on rheumatoid arthritis candidate otilimab – which is licensed to GlaxoSmithKline – and 60% of future royalties on Roche’s Alzheimer’s hope gantenerumab. Added to that, it takes a 3% share of any future royalties from pelabresib and CPI-0209.

59

59

pharmaphorum

DECEMBER 23, 2020

The American Society of Clinical Oncology (ASCO) annual conference was one of the highlights of the year in cancer research and the fact it was held virtually did not distract from some stunning clinical lung cancer trial results presented by AstraZeneca.

FDA 78

FDA Chemotherapy Compounding Vaccines 78

The Checkup by Singlecare

OCTOBER 20, 2023

Sources Traditional medicine in India , Journal of Traditional Chinese Medical Sciences (2021) The effects of Shilajit supplementation on fatigue-induced decreases in muscular strength and serum hydroxyproline levels , Journal of the International Society of Sports Nutrition (2019) Natural dibenzo-α-pyrones and their bioactivities , Molecules , (2014) (..)

Immunization 105

Immunization FDA 105

pharmaphorum

AUGUST 10, 2021

The team – led by Prof Zoe Kourtzi of the university and Alan Turing Institute – told the BBC that the AI could make it possible to start treatment earlier to slow down progression of Alzheimer’s disease and other forms of dementia. ” The post Cambridge team says AI could diagnose dementia with one scan appeared first on. .

Hospitals 137

Hospitals 137

The Guardian - Pharmaceutical Industry

JULY 17, 2023

As results show 35% slowing in cognitive decline, health leaders say swift decisions crucial What impact will the Alzheimer’s drug donanemab have? The final results from a landmark study confirmed that donanemab, made by Eli Lilly, slowed cognitive decline in Alzheimer’s patients by 35%.

70

70

The Guardian - Pharmaceutical Industry

NOVEMBER 30, 2022

Patients unlikely to receive lecanemab before 2026 and health service does not yet have necessary infrastructure Drug slows cognitive decline in Alzheimer’s patients, study reveals A reorganisation of NHS dementia care is needed to ensure UK patients can receive a groundbreaking drug that slows the progression of Alzheimer’s disease, doctors say.

69

69

The Guardian - Pharmaceutical Industry

DECEMBER 31, 2023

Finding drugs that mimic the benefits of a workout has long been a goal of science.

Hospitals 54

Hospitals 54

The Guardian - Pharmaceutical Industry

MAY 3, 2023

Indeed, Alzheimer’s Society first funded Prof John Hardy’s amyloid research back in 1989, and it is only now that we are seeing the first amyloid-targeting treatments that show evidence of slowing the progression of Alzheimer’s disease.

43

43